title: Classical and atypical binding sites for beta-adrenoceptor ligands and activation of adenylyl cyclase in bovine skeletal muscle and adipose tissue membranes.
abstract: 1. The radioligand [125I]-iodocyanopindolol ([125I]-ICYP) was used under standard ligand binding conditions, to detect beta 1- and beta 2-adrenoceptors in membrane preparations from bovine skeletal muscle and adipose tissue. High concentrations of [125I]-ICYP were also used, to identify an 'atypical' binding site in skeletal muscle. Finally, adenosine 3':5'-cyclic monophosphate (cyclic AMP) production was measured in the same membrane preparations, to determine the relationship between the beta-adrenoceptor sub-types present and the production of this second-messenger. 2. According to the results of radioligand binding studies, both skeletal muscle and adipose tissue membranes have beta 2-adrenoceptors, characterized by a high affinity for the beta 2-selective antagonist, ICI 118551 (pK 8.3 and 8.6 respectively); and a low affinity for the beta 1-selective antagonist CGP 20712A (pK 5.2 in both tissues). Antagonism of (-)-isoprenaline-stimulated cyclic AMP production by low concentrations of ICI 118551, yielded pseudo pA2 values in muscle and adipose tissue of 7.6 and 8.7 respectively, confirming that beta 2-adrenoceptors in these tissues are linked to the production of the second-messenger. 3. Although beta 1-adrenoceptors could not be detected in either skeletal muscle or adipose tissue membranes by use of ligand binding techniques, high pseudo pA2 values were obtained (8.0 and 8.2 respectively), when CGP 20712A was used to block the stimulation of cyclic AMP production by (-)-isoprenaline. This finding is consistent with the presence in both tissues of a population of beta 1-adrenoceptors which is small, but efficiently coupled to the second-messenger. 4.In addition to identifying standard beta 1- and beta 2-adrenoceptors, it was also established that skeletal muscle membranes have an 'atypical' binding site which has a relatively low affinity for [125]-ICYP(pK8.84), but which exists in abundance. At high concentrations of radioligand, the 'atypical' site accounted for 89% of the total [125I]-ICYP binding sites present.5. The results of second-messenger studies do not support the hypothesis that skeletal muscle or adipose tissue membranes contain functional beta 3-adrenoceptors: based on the failure of a beta 3-adrenoceptor-selective agonist (BRL 37344) to stimulate cyclic AMP production, the absence of a biphasic response to (-)-isoprenaline, and the observation that cyclic AMP production was not resistant to blockade by either ICI 118551 or CGP20712A.6. It is concluded that data from radioligand binding studies do not accurately reflect the contribution made by beta 1- and beta 2-adrenoceptors to cyclic AMP production in bovine skeletal muscle and adipose tissue membranes. Furthermore, the 'atypical' [125I]-ICYP binding site identified in bovine skeletal muscle does not represent a functional bovine beta 3-adrenoceptor.
authors.affiliation: Tropical Cattle Research Centre, CSIRO Division of Tropical Animal Production, Rockhampton, Queensland, Australia.
authors.forename: M N
authors.initials: MN
authors.lastname: Sillence
authors.forename: M L
authors.initials: ML
authors.lastname: Matthews
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism*; D000273:Adipose Tissue / Q000187:drug effects / Q000201:enzymology* / Q000648:ultrastructure*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D002417:Cattle; D000242:Cyclic AMP / Q000096:biosynthesis; D004789:Enzyme Activation; D005260:Female; D007457:Iodine Radioisotopes; D020120:Iodocyanopindolol; D007545:Isoproterenol / Q000494:pharmacology; D007700:Kinetics; D008566:Membranes / Q000187:drug effects / Q000201:enzymology / Q000648:ultrastructure; D009132:Muscles / Q000187:drug effects / Q000201:enzymology* / Q000648:ultrastructure*; D010869:Pindolol / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D011869:Radioligand Assay; D018342:Receptors, Adrenergic, beta-1 / Q000187:drug effects / Q000378:metabolism*; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects / Q000378:metabolism*; D015290:Second Messenger Systems / Q000187:drug effects / Q000502:physiology
chemical_list: D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D007457:Iodine Radioisotopes; D018342:Receptors, Adrenergic, beta-1; D018343:Receptors, Adrenergic, beta-2; D020120:Iodocyanopindolol; D010869:Pindolol; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D007545:Isoproterenol